THE ROLE OF CD20+ T LYMPHOCYTES IN THE PATHOGENESIS OF MULTIPLE SCLEROSIS



Cite item

Full Text

Abstract

AbstractCD3+CD20+ T lymphocytes are a population of T cells that, along with standard T cell markers, express the atypical membrane molecule CD20 (a traditional B cell marker). These cells were identified not so long ago and are currently being actively studied. Normally, they constitute up to 3–5% of the CD3+ T cell compartment in human peripheral blood, and are also found in primary and secondary lymphoid organs, cerebrospinal fluid, brain tissue and liver. In healthy individuals, CD3+CD20+ T cells are heterogeneous and contain a lower proportion of CD4+ cells, but produce higher levels of GM-CSF, IFN-γ, IL-17, TNF-α, IL-4, IL-10, adhesion molecules and chemokine receptors than CD3+CD20 T cells, indicating a highly activated proinflammatory phenotype with properties potentially promoting their pathogenic infiltration into the CNS. Recent studies have established the pathogenic behavior of CD3+CD20+ T cells in a wide range of diseases, including hematological and non-hematological CD20+ T cell malignancies and HIV, as well as autoimmune pathologies, in particular multiple sclerosis, a disabling inflammatory neurodegenerative disease that is accompanied by damage to the myelin sheath nerve fibers. CD20 positive T cells are detected in patients with multiple sclerosis in the peripheral blood, cerebrospinal fluid (occur at a frequency similar to that of B cells and show a correlation with disease severity) and white matter of the brain. CD20 positive T lymphocytes in the peripheral blood of patients with multiple sclerosis have been shown to produce high levels of IFN-γ and IL-17А, which are two proinflammatory cytokines involved in the pathogenesis of this disease. It is possible that CD20+ T cells represent a separate subpopulation of Th17 cells, the so-called Th1-polarized Th17, which are the product of redifferentiation of Th17 cells into Th1 and combine the phenotypic characteristics of both populations. And the expression of CD20 T cells may be a valuable marker that determines the target subpopulation of such pathogenic T cells, as well as serve as a target for therapy of autoimmune diseases.

About the authors

Natalia Sergeevna Glebezdina

Perm Federal Research Center, Institute of Ecology and Genetics of Microorganisms, Ural Branch of the Russian Academy of Sciences

Author for correspondence.
Email: glebezdina_n@mail.ru
ORCID iD: 0000-0002-9891-0509
SPIN-code: 3985-4887
Scopus Author ID: 55633218800
ResearcherId: R-8025-2016

candidate of biology, junior researcher of laboratory of immunoregulation

Russian Federation, 614081,г. Пермь, ул. Голева, 13

References

  1. Kuklina E.M., Glebezdina N.S. Markers of Th1 polarized Th17 cells (literature review). Acta biomedica scientifica, 2023, Vol. 8, no. 3, pp. 55-62.
  2. Chen Q., Yuan S., Sun H., Peng L. CD3(+)CD20(+) T cells and their roles in human diseases. Hum. Immunol., 2019, Vol. 80, no. 3, pp. 191-194. https://doi.org/10.1016/j.humimm.2019.01.001
  3. Cosmi L., Liotta F., Maggi E., Romagnani S., Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy, 2011, Vol. 66, no. 8, pp. 989-998. https://doi.org/10.1111/j.1398-9995.2011.02576.x
  4. de Bruyn M., Wiersma V.R., Wouters M.C.A., Samplonius D.F., Klip H.G., Helfrich W., Nijman H.W., Eggleton P., Bremer E. CD20+ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncoimmunology, 2015, Vol. 4, no. 4, e999536. https://doi.org/10.1080/2162402X.2014.999536
  5. Gingele S., Skripuletz T., Jacobs R. Role of CD20+ T cells in multiple sclerosis: implications for treatment with ocrelizumab. Neural. Regen. Res., 2020, Vol. 15, no. 4, pp. 663-664. https://doi.org/10.4103/1673-5374.266913
  6. Havrdova E., Belova A., Goloborodko A., Tisserant A., Wright A., Wallstroem E., Garren H., Maguire R.P, Johns D.R. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J. Neurol., 2016, Vol. 263, no. 7, pp. 1287-1295. https://doi.org/10.1007/s00415-016-8128-x
  7. Jadidi-Niaragh F., Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand. J. Immunol., 2011, Vol. 74, no. 1, pp. 1-13. https://doi.org/10.1111/j.1365-3083.2011.02536.x
  8. Lee A.Y.S. CD20+ T cells: an emerging T cell subset in human pathology. Inflamm. Res. 2022, Vol. 71, no. 10-11, pp. 1181-1189. https://doi.org/10.1007/s00011-022-01622-x
  9. Ochs J., Nissimov N., Torke S., Freier M., Grondey K., Koch J., Klein M., Feldmann L., Gudd C., Bopp T., Häusser-Kinzel S., Weber M.S. Proinflammatory CD20+ T cells contribute to CNS-directed autoimmunity. Sci. Transl. Med., 2022, Vol. 14, no. 638, eabi4632. https://doi.org/10.1126/scitranslmed.abi4632
  10. Quendt C., Ochs J., Häusser-Kinzel S., Häusler D., Weber M.S. Proinflammatory CD20(+) T cells are differentially affected by multiple sclerosis therapeutics. Ann. Neurol. 2021, Vol. 90, no. 5, pp. 834-839. https://doi.org/10.1002/ana.26216
  11. Ramstein J., Broos C.E., Simpson L.J., Ansel K.M., Sun S.A., Ho M.E., Woodruff P.G., Bhakta N.R., Christian L., Nguyen C.P., Antalek B.J., Benn B.S., Hendriks R.W., van den Blink B., Kool M., Koth L.L. IFN-γ-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am. J. Respir. Crit. Care. Med., 2016, Vol. 193, no. 11, pp. 1281-1291. https://doi.org/10.1164/ rccm.201507-1499OC
  12. Reich D.S., Lucchinetti C.F., Calabresi P.A. Multiple Sclerosis. N. Engl. J. Med., 2018, Vol. 378, no. 2, pp. 169-180. https://doi.org/10.1056/NEJMra1401483.
  13. Schuh E., Berer K., Mulazzani M., Feil K., Meinl I., Lahm H., Krane M., Lange R., Pfannes K., Subklewe M., Gürkov R., Bradl M., Hohlfeld R., Kümpfel T., Meinl E., Krumbholz M. Features of human CD3+CD20+ T cells. J. Immunol., 2016, Vol. 197, no. 4, pp. 1111-1117. https://doi.org/10.4049/jimmunol.1600089
  14. von Essen M.R., Ammitzboll C., Hansen R.H., Petersen E.R.S., McWilliam O., Marquart H.V., Damm P., Sellebjerg F. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain, 2019, Vol. 142, no. 1, pp.120-132. https://doi.org/10.1093/brain/awy301
  15. Wilk E., Witte T., Marquardt N., Horvath T., Kalippke K., Scholz K., Wilke N., Schmidt R.E., Jacobs R. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum., 2009, Vol. 60, no. 12, pp. 3563-3571. https://doi.org/10.1002/art.24998

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Glebezdina N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies